Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on July 3, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp229
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
84/3/461    most recent
cvp229v2
cvp229v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wang, Y.
Right arrow Articles by He, G.-W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Y.
Right arrow Articles by He, G.-W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

A New Transmyocardial Degradable Stent Combined with Growth Factor, Heparin, and Stem Cells in Acute Myocardial Infarction

Ying Wang, MPhil1,2, Xiao-Cheng Liu, MD1,2,*, Guang-Wei Zhang, MD1,2, Jian Zhao, MD1,2, Jie-Min Zhang, MD2, Rong-Fang Shi, MD3, Yun-Zhou Huang, MD4, Chun-Hua Zhao, MD,PhD5, Tian-Jun Liu, PhD6, Cun-Xian Song, MD6, Feng Lü, MD6, Qin Yang, MD,PhD7 and Guo-Wei He, MD,PhD,DSc7,*

1 Chinese Academy of Medical Sciences Peking Union Medical College, Tianjin, China
2 Department of Surgery, TEDA International Cardiovascular Hospital, Tianjin, China
3 Department of Nuclear Medicine, TEDA International Cardiovascular Hospital, Tianjin, China
4 Ultrasound, TEDA International Cardiovascular Hospital, Tianjin, China
5 Institute of Basic Medical Sciences, Center of Excellence in Tissue Engineering
6 Institute of Biomedical Engineering, Peking Union Medical College, Beijing, China
7 TEDA International Cardiovascular Hospital, Nankai University Medical College, Tianjin & Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China & Oregon Health & Science University, Portland, OR, U.S.A

* Co-Corresponding Authors Professor Xiao-Cheng Liu, MD, Professor Guo-Wei He, MD, PhD, DSc, Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Tianjin, China, No.61, the Third Avenue, TEDA, Tianjin, China 300457, Tel: 86-22-6520 9089, Fax: 86-22-6520 8732, E-mail: gwhe{at}cuhk.edu.hk or liuxc{at}tedaich.com

Aims: We developed a new method — transmyocardial drilling revascularization (TMDR) with absorbable stent incorporated with basic fibroblast growth factor (bFGF) and heparin. The present study tested the effect of this method with transplantation of bone marrow-derived stem cells (BMSCs) in acute myocardial infarction.

Methods: Infarction was produced in miniswines by ligating the left anterior descending coronary artery (LAD). TMDR of 3.0 mm in diameter were made by mechanical drilling in the infarcted area. The animals that had LAD ligation and were divided into 6 groups according to the procedures followed (n=6 in each): Control&; T (TMDR); C (cell implantation); TS (TMDR+stent implantation); TC (TMDR+cell implantation); TSC (TMDR+stent implantation+cell implantation). Left ventricular (LV) function, myocardial perfusion, vascular density, and histological and morphological analyses were evaluated preoperatively and at 30 min and 6 weeks postoperatively.

Results: Six weeks after operation, the above indices were significantly better in the TSC group than in other groups (P<0.001 compared to the control group and p<0.05 or 0.01 compared to the TS and TC groups), although TS and TC also showed better results than the control group (p<0.05).

Conclusion: We have demonstrated in a pig model that an intramyocardial stent implanted with slow release of bFGF, heparin, and BMSC transplantation may significantly increase left ventricular function, cardiac blood flow, and vascular density. Therefore, the present study may provide a new method for the surgical treatment of myocardial infarction.

KEYWORDS Myocardial infarction; Transmyocardial revascularization; Heparin; basic fibroblast growth factor; Stem cell transplantation

Time for primary review: 31 Days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.